Opinion|Videos|July 22, 2024
The Potential Benefits of RSV Vaccine Approval for Adults Aged 50-59
As phase 3 data for the RSV vaccine are leading the FDA to consider expanding the age range to include patients aged 50-59, the panel discusses the potential clinical and economic benefits.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- What is the important phase 3 data for the RSV vaccine that is leading the FDA to consider an expanded age range to 50-59?
- How would RSV vaccine approval for adults aged 50-59 improve the clinical and economic impact of the disease?
- What will the best practices be for identifying patients who are eligible for receiving the RSV vaccine with the potential updated indication?
- How should payers adjust coverage decisions for RSV vaccines in patients aged 50-59 if this expanded indication is approved?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
- How should the ACIP/CDC incorporate a potential indication expansion into their recommendations?
Advertisement
Related to this article
Ultimately, causality could not be established due to lack of data on disease severity and socioeconomic status, among others.
GRADE meta-analysis: hepatitis A vaccine blocks 96% in pre-exposure vaccination; outbreak response uses millions of doses, but post-exposure prophylaxis evidence is weak.
Alcohol abuse was the strongest post-trauma psychiatric predictor of cardiovascular events, with mood disorders more prominent among women.
Individuals with or at risk for arrhythmogenic cardiomyopathy had no added risk of ventricular arrhythmia from strength training, unlike endurance exercise.
A systematic review finds people with narcolepsy and idiopathic hypersomnia often stay employed but face work impairment and limited workplace support.
Laura Fabbri, MD, discusses bridging idiopathic pulmonary fibrosis (IPF) and oncology research and putting patients at the center of trial design.
Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.
Karolinska Institutet reports ROR1 inhibitor KAN571C wipes out double‑resistant MCL after ibrutinib/venetoclax, spotlighting a promising target.
Advertisement
Advertisement